Sharma Akhil, Mannan Ashi, Singh Thakur Gurjeet
Chitkara College of Pharmacy, Chitkara University, Punjab, 140401, Rajpura, India.
Metab Brain Dis. 2025 Jun 7;40(5):218. doi: 10.1007/s11011-025-01642-6.
Insulin resistance (IR) impairs glucose uptake and metabolism, whereas amyloidogenesis, the formation of abnormal protein aggregation, forming insoluble fibrils called amyloids, which are linked with numerous neurodegenerative diseases (NDDs) such as Alzheimer's disease (AD), Huntington disease's (HD), Parkinson's disease (PD) and Prion's disease. This review explores how IR promotes amyloidogenesis by disrupting cholesterol homeostasis and enhancing Amyloid beta (Aβ) production and aggregation. Specifically, we examine the role of ATP-binding cassette (ABC) transporters in cholesterol homeostasis along with their impact on insulin signaling pathways, highlights how their dysregulation can lead to IR, a significant contributor to the development of amyloidogenesis, a key factor in causing NDDs. We explore the novel molecular mechanisms linking IR and Aβ aggregation, focusing on the interplay between ABC transporters and Amyloid precursor protein (APP) processing. Furthermore, we also explore emerging evidence linking ABC transporters to oxidative stress, inflammation and mitochondrial dysfunction critical factors in the development of amyloidogenesis. Additionally, this review also discusses potential therapeutic strategies targeting ABC transporters to mitigate IR and reduce amyloid burden by various mechanisms including Insulin receptors/IRS-1 signaling, Phosphatidylinositol3kinase-Protein kinase-B (PI3K/AKT), Mitogen-activated protein kinases (MAPK), c-Jun N-terminal kinase (JNK), Glycogen synthase kinase 3 (GSK3), mammalian Target of Rapamycin (mTOR), Insulin-Degrading Enzyme (IDE), Advanced glycation end products (AGEs), Glucose transporters (GLUTs), Apolipoprotein E (ApoE), Peroxisome proliferator-activated receptors (PPARs), Adiponectin, Mitochondrial dysfunctioning, AMP-activated protein kinase (AMPK) Wingless-related integration site/beta-catenin (Wnt/β-catenin) and Sirtuin1 (SIRT1). These insights provide new possibilities for developing targeted therapies against neurodegenerative diseases associated with IR and amyloid accumulation.
胰岛素抵抗(IR)会损害葡萄糖摄取和代谢,而淀粉样蛋白生成,即异常蛋白质聚集体的形成,会形成称为淀粉样蛋白的不溶性纤维,这与许多神经退行性疾病(NDDs)相关,如阿尔茨海默病(AD)、亨廷顿病(HD)、帕金森病(PD)和朊病毒病。本综述探讨了IR如何通过破坏胆固醇稳态、增强β淀粉样蛋白(Aβ)的产生和聚集来促进淀粉样蛋白生成。具体而言,我们研究了ATP结合盒(ABC)转运蛋白在胆固醇稳态中的作用及其对胰岛素信号通路的影响,强调了它们的失调如何导致IR,而IR是淀粉样蛋白生成发展的重要促成因素,也是导致NDDs的关键因素。我们探索了将IR与Aβ聚集联系起来的新分子机制,重点关注ABC转运蛋白与淀粉样前体蛋白(APP)加工之间的相互作用。此外,我们还探讨了将ABC转运蛋白与氧化应激、炎症和线粒体功能障碍联系起来的新证据,这些都是淀粉样蛋白生成发展中的关键因素。此外,本综述还讨论了针对ABC转运蛋白的潜在治疗策略,以通过各种机制减轻IR并减少淀粉样蛋白负担,这些机制包括胰岛素受体/胰岛素受体底物-1(IRS-1)信号传导、磷脂酰肌醇3激酶-蛋白激酶B(PI3K/AKT)、丝裂原活化蛋白激酶(MAPK)、c-Jun氨基末端激酶(JNK)、糖原合酶激酶3(GSK3)、哺乳动物雷帕霉素靶蛋白(mTOR)、胰岛素降解酶(IDE)、晚期糖基化终末产物(AGEs)、葡萄糖转运蛋白(GLUTs)、载脂蛋白E(ApoE)、过氧化物酶体增殖物激活受体(PPARs)、脂联素、线粒体功能障碍、AMP活化蛋白激酶(AMPK)、无翅型相关整合位点/β-连环蛋白(Wnt/β-catenin)和沉默调节蛋白1(SIRT1)。这些见解为开发针对与IR和淀粉样蛋白积累相关的神经退行性疾病的靶向治疗提供了新的可能性。
J Parkinsons Dis. 2024
Mol Neurobiol. 2025-8-16
Int J Mol Sci. 2024-9-16
Inflammopharmacology. 2024-10
Cell Rep Med. 2024-6-18
Curr Drug Res Rev. 2024-6-14